ALK/TRK Inhibitor TSR-011

Known as: TSR-011 
An orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2016
0120142016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
The tropomyosin receptor kinase (TRK) family includes TRKA, TRKB, and TRKC proteins, which are encoded by NTRK1, NTRK2 and NTRK3… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 3
Is this relevant?
Review
2016
Review
2016
The treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring chromosomal rearrangements of ALK… (More)
Is this relevant?
Review
2015
Review
2015
PURPOSE OF REVIEW Crizotinib now is accepted as the standard first-line treatment of ALK-rearranged lung adenocarcinomas. To… (More)
Is this relevant?
Review
2015
Review
2015
The therapeutic targeting of anaplastic lymphoma kinase (ALK) has been a burgeoning area of research since 2007 when ALK fusions… (More)
Is this relevant?
Review
2014
Review
2014
The treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring chromosomal rearrangements of anaplastic… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?